Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

China Shenghuo to Restate Financial Results

publication date: Aug 20, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

China Shenghuo Pharmaceutical Holdings, Inc. will restate its financial reports from the past twelve months, saying that the company has discovered errors in sales commission advances and trade receivables. The Audit Committee and an independent counsel will review Shenghuo’s internal controls and the personnel who are involved. The company did not hint at the magnitude of the restatement, though it does expect to complete the review and present restated results within two months. More details...

Stock Symbol: (AMEX: KUN)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...